The Multicentre Selective Lymphadenectomy Trial - 3

The goal of this clinical trial is to demonstrate that there is no difference (non-inferiorty) in the 2 year recurrence-free survival (RFS) between 2 different surgical approaches for clinical Stage III melanoma. Following 6 weeks of standard neaodjuvant immunotherapy, patients will undergo either selective index lymph node resection (ILN) (identified at baseline as the largest affected lymph node) or the standard of care therapeutic lymph node dissection (TLND). The secondary aims are to assess if patients who are managed without TLND will have a reduction in surgical complications (less woun

Trial Details

NCT ID
NCT07049276
Phase
NA
Sponsor
Melanoma Institute Australia
Status
RECRUITING
Cancer Type
Melanoma
Interventions
  • Index lymph node resection
  • Therapeutic lymph node dissection
Locations (sample)
  • Los Angeles, California, United States|34.05223,-118.24368
  • Newcastle, New South Wales, Australia|-32.92953,151.7801
  • Wollstonecraft, New South Wales, Australia|-33.8328,151.18981
  • Murdoch, Western Australia, Australia|-32.06987,115.83757
  • Toronto, Ontario, Canada|43.70643,-79.39864

Key Eligibility Criteria

  • Male or female patients ≥ 18 years of age at the time of consent
  • Written informed consent
  • Cytologically or histologically confirmed, resectable pathological Stage IIIB, C or D (Any T, N1b, N2b, N2c, N3b, or N3c) cutaneous or unknown prim…
  • A minimum of one macroscopic lymph node, defined as:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →